Grants / Department of Health and Human Services / National Institutes of Health

PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Closed Closed August 19, 2024 Opportunity PAR-21-233 ☆ Save

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.

• Award amountsNot given on Grants.gov
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to small businesses.

• Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

More grants for small businesses.

Is this a realistic fit?

• Most of the money in the 10 programs behind this notice (73% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Category: Education, Health, Income Security and Social Services.

Other programs behind this notice

• Drug Use and Addiction Research Programs 93.279
  $7.3 billion in five years
• Child Health and Human Development Extramural Research 93.865
  $6.0 billion in five years
• Vision Research 93.867
  $3.4 billion in five years
• Alcohol Research Programs 93.273
  $2.2 billion in five years
• Oral Diseases and Disorders Research 93.121
  $1.9 billion in five years
• Discovery and Applied Research for Technological Innovations to Improve Human Health 93.286
  $1.8 billion in five years
• Research and Training in Complementary and Integrative Health 93.213
  $575 million in five years

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.